The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Open accessAbstract
BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. METHODS: In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy. The primary end point was investigator-assessed progression-free survival. RESULTS: The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001). The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001). Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49). The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%). CONCLUSIONS: Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number, NCT02151981 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Own result · 13 Not checked yet · 8 Own method · 3 Own interpretation · 1 Sources not found · 1 Check pending
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the basis of investigator assessment, the median response duration was 9.7 months (95% CI, 8.3 to 11.6) in the osimertinib group and 4.1 months (95% CI, 3.0 to 5.6) in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).”
- Also stated in: § EFFICACY · plain
“The response rate was significantly better in the osimertinib group (71%; 95% CI, 65 to 76) than in the platinum–pemetrexed group (31%; 95% CI, 24 to 40) (odds ratio, 5.39; 95% CI, 3.47 to 8.48; P<0.001) (Table 2).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § EFFICACY · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvement in outcomes with osimertinib over platinum–pemetrexed in the tumor and plasma ctDNA T790M-positive subgroup was similar to that in the intention-to-treat population.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most commonly reported adverse events in the platinum–pemetrexed group were nausea (in 67 patients [49%]), decreased appetite (in 49 [36%]), constipation (in 47 [35%]), and anemia (in 41 [30%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 67- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%).”
- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
“Fewer patients reported adverse events of grade 3 or more in the osimertinib group than in the platinum–pemetrexed group (63 [23%] vs. 64 [47%]).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > RESULTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § SAFETY AND ADVERSE EVENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In a mixed model for repeated-measures analysis, patient-reported outcomes were better in the osimertinib group than in the platinum–pemetrexed group across five prespecified symptoms during the overall period from randomization until 6 months (Table S4 in the Supplementary Appendix).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar finding was observed in the subgroup of patients with T790M-positive status on both tumor and plasma analyses (89 of 116 patients [77%] vs. 22 of 56 patients [39%]; odds ratio, 4.96; 95% CI, 2.49 to 10.15; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaincorrelationaln = 116 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Osimertinib was associated with a lower rate of adverse events leading to permanent discontinuation than was platinum–pemetrexed (in 19 patients [7%] and 14 patients [10%], respectively).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plaincorrelationaln = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival among patients with tumor and plasma T790M-positive status was 8.2 months in the osimertinib group versus 4.2 months in the platinum–pemetrexed group (hazard ratio, 0.42; 95% CI, 0.29 to 0.61) (Fig. 1C).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fatal adverse events were reported in 4 patients in the osimertinib group (respiratory failure in 2, pneumonitis in 1, and ischemic stroke in 1). One fatal adverse event of hypovolemic shock was reported in the platinum–pemetrexed group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 12
- Probably not a substantial claim. 7
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A prolongation in the QT interval was recorded in 10 patients (4%) in the osimertinib group and 1 patient (1%) in the platinum–pemetrexed group, with all events of grade 1 or 2 in severity except for one grade 3 event in the osimertinib group.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard ratio for progression-free survival favored osimertinib across all predefined subgroups that were analyzed (hazard ratio, <0.50 for each subgroup) (Fig. 2), including patients with CNS metastases (median duration of progression-free survival, 8.5 months vs. 4.2 months; hazard ratio, 0.32; 95% CI, 0.21 to 0.49) (Fig. 1B).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The duration of progression-free survival according to blinded independent central review was consistent with the investigator-assessed durations, with a median of 11.0 months versus 4.2 months (adjusted hazard ratio, 0.28; 95% CI, 0.20 to 0.38; P<0.001).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > EFFICACY
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interstitial lung disease–like adverse events were reported in 10 patients (4%) in the osimertinib group (nine events of grade 1 or 2 in severity and one death) and in 1 patient (1%) in the platinum–pemetrexed group (one grade 3 event).”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > RESULTS > SAFETY AND ADVERSE EVENTS
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the patients who underwent randomization were included in the intention-to-treat population, which was used for all efficacy analyses.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, adverse events tended to be more severe in the platinum–pemetrexed group, despite the longer treatment duration with osimertinib.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety analysis included all the patients in the intention-to-treat population who had received at least one dose of a trial drug and for whom data were available after the administration of the drug.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The presence of the T790M variant reduces binding of first-generation or second-generation EGFR-TKIs to the ATP-binding pocket of EGFR, thereby reducing EGFR-TKI–mediated inhibition of downstream signaling and potentially leading to disease progression.17–19”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [17] Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070– 5. 18227510 PMC2538882 source
- Not checked yetcites [18] Sos ML, Rode HB, Heynck S, Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010; 70: 868– 74. 20103621 source
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These findings were confirmed in a pooled analysis of two subsequent phase 2 studies of osimertinib (at a dose of 80 mg once daily) in 411 patients with T790M-positive non–small-cell lung cancer, in which the response rate was 66% on blinded independent central review and the median duration of progression-free survival was 11.0 months.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
plainn = 411- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Conference on Harmonisation), applicable regulatory requirements, and the policy on bioethics and human biologic samples of the trial sponsor, AstraZeneca.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL OVERSIGHT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We determined that 221 events of progression or death would provide a power of 80% to reject the null hypothesis of no significant difference in the duration of progression-free survival between the two treatment groups, assuming a treatment effect hazard ratio of 0.67 with a P value of 0.05 indicating two-sided statistical significance.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > STATISTICAL ANALYSIS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Osimertinib is an oral, irreversible EGFR-TKI that is selective for both EGFR and T790M resistance mutations with activity in the central nervous system (CNS).19–21”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [19] Cross DA, Ashton SE, Ghiorghiu S, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046– 61. 24893891 PMC4315625 source
- Not checked yetcites [20] Ballard P, Yates JW, Yang Z, Pre-clinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016; 22: 5130– 40. 27435396 source
- Not checked yetcites [21] Yang JC-H, Kim D-W, Kim S-W, Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 2016; 34: Suppl: 9002 abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Among patients with advanced non–small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy.1–4”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [1] Masters GA, Temin S, Azzoli CG, Systemic therapy for Stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015; 33: 3488– 515. 26324367 PMC5019421 source
- Not checked yetcites [2] Novello S, Barlesi F, Califano R, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: Suppl 5: v1– v27. 27664245 source
- Not checked yetcites [3] Tan DS, Yom SS, Tsao MS, The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 2016; 11: 946– 63. 27229180 source
- Not checked yetcites [4] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: NSCLC (version 3.2017). 2016 (http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). 28188192 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A sensitivity analysis of progression-free survival by blinded independent central review was conducted.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL END POINTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients were stratified according to Asian or non-Asian race and were randomly assigned in a 2:1 ratio to receive oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles.”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > METHODS > TRIAL DESIGN AND TREATMENT
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In AURA3, the safety profile for osimertinib was consistent with that reported previously and differed from that in the platinum–pemetrexed group.23”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > DISCUSSION
What the sources say
- Not checked yetcites [23] Yang J, Ramalingam SS, Jänne PA, Cantarini M, Mitsudomi T. LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol 2016; 11: Suppl: S152– S153. source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the phase 1 component of AURA, a phase 1/2 trial (ClinicalTrials.gov number, ), the objective response rate for osimertinib in patients with T790M-positive non–small-cell lung cancer was 61%; the median duration of progression-free survival was 9.6 months.22”
§ Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [22] Jänne PA, Yang JC-H, Kim D-W, AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med 2015; 372: 1689– 99. 25923549
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Platinum-pemetrexed was the standard of care for patients with T790M-positive advanced NSCLC after first-line EGFR-TKI at the time of trial initiation.
“Chemotherapy was the standard control at the time of trial initiation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In T790M-positive tumors, following progression after first- or second-generation EGFR TKIs, second-line osimertinib has demonstrated significant efficacy compared with chemotherapy (median PFS: 10.1 vs 4.4 months; HR, 0.30 (95% CI, 0.23‒0.40), P < 0.001).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [48]
Experimental — accuracy not yet measuredIn the citing paper
“In addition to being used alone, osimertinib is also being studied in combination with other targeted therapies for NSCLC, such as inhibitors of the Met, Bcl-2, and MAPK pathways.138–140”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [140]
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“Across clinical trials of first-line targeted therapy for oncogene-addicted subgroups of NSCLC, rates of objective response [G] typically range between 50% and 83% and complete responses [G] are rare; in addition, some patients exhibit de novo resistance16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [21]
In the citing paper
“In a randomized phase III trial[3], osimertinib significantly improved both progression-free survival (PFS) and objective response rate (ORR) when compared to platinum-pemetrexed chemotherapy for T790M-positive non-small cell lung cancer (NSCLC) after progression on 1st or 2nd generation EGFR-TKIs.”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [3]
In the citing paper
“In the AURA3 phase III trial, osimertinib demonstrated signi fi cantly higher ef fi cacy than platinum-based chemotherapy in patients with T790M-positive NSCLC. 14”
From Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) (2020) · cites this paper as [14]
In the citing paper
“Osimertinib was granted accelerated approval by the FDA in 2015 as a second-line treatment for NSCLC, and was approved as a first-line treatment for metastatic NSCLC in 2018 (ref.49).”
From Advances in covalent drug discovery (2022) · cites this paper as [49]
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Research works printed but not linked: 1
- Soria J, 2015, J Thorac Oncol, 10, S207
Cited by
Sorted by citations
Items 801–900 of 1,003
Guo, W., Sun, S., Guo, L., Song, P., Xue, X., Zhang, H., Zhang, G., Li, R., Gao, Y., Qiu, B., et al. (2020) · DNA and Cell Biology · doi:10.1089/dna.2019.5291 · Cited by 31
Minari, R., Mazzaschi, G., Bordi, P., Gnetti, L., Alberti, G., Altimari, A., Gruppioni, E., Sperandi, F., Parisi, C., Guaitoli, G., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.021 · Cited by 31
The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
Zhao, C., Jiang, T., Li, J., Wang, Y., Su, C., Chen, X., Ren, S., Li, X., & Zhou, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-359 · Cited by 31
Fukuhara, T., Saito, H., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, P. M., Yoshimori, K., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102861 · Cited by 31
Nishio, M., Seto, T., Reck, M., Garon, E. B., Chiu, C., Yoh, K., Imamura, F., Park, K., Shih, J., Visseren‐Grul, C., et al. (2020) · Cancer Science · doi:10.1111/cas.14655 · Cited by 31
Lamy, P., van der Leest, P., Lozano, N., Becht, C., Duboeuf, F., Groen, H. J. M., Hilgers, W., Pourel, N., Rifaela, N., Schuuring, E. M. D., et al. (2020) · Cancers · doi:10.3390/cancers12103002 · Cited by 31
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
Magios, N., Bozorgmehr, F., Volckmar, A., Kazdal, D. N., Kirchner, M., Herth, F. J. F., Heußel, C. P., Eichhorn, F., Meister, M. A., Muley, T., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921996509 · Cited by 31
Progress and application of circulating tumor cells in non-small cell lung cancer
Qian, H., Zhang, Y., Xu, J., He, J., & Gao, W. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.005 · Cited by 31
Muthusami, S., Sabanayagam, R., Periyasamy, L., Bharathi, M., & Park, W. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.117 · Cited by 31
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Vyse, S., & Huang, P. H. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2016397 · Cited by 33
Stanzione, M., Zhong, J., Wong, E., LaSalle, T. J., Wise, J. F., Simoneau, A., Myers, D. T., Phat, S., Sade-Feldman, M., Lawrence, M. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn1229 · Cited by 32
Liang, L., He, H., Jiang, S., Liu, Y., Huang, J., Sun, X., Li, Y., Jiang, Y., & Li, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810415 · Cited by 31
Emdal, K. B., Dittmann, A., Reddy, R. J., Lescarbeau, R. S., Moores, S. L., Laquerre, S. G., & White, F. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0413 · Cited by 33
Circulating DNA in EGFR-mutated lung cancer
Singh, A. P., Li, S., & Cheng, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.07.10 · Cited by 31
Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
Harvey, R. D., Aransay, N. R., Isambert, N., Lee, J., Arkenau, H., Vansteenkiste, J., Dickinson, P. A., Bui, K., Weilert, D. K., So, K., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13753 · Cited by 31
Zhou, C., Yuan, Z., Ma, W., Qi, L., Mahavongtrakul, A., Li, Y., Li, H., Gong, J., Fan, R. R., Li, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0671-8 · Cited by 31
Park, J. S., Hong, M. H., Chun, Y. J., Kim, H. R., & Cho, B. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.030 · Cited by 31
Self-citationGyawali, B., D’Andrea, E., Franklin, J. M., & Kesselheim, A. S. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7345 · Cited by 33
Liam, C. K. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.12.68 · Cited by 31
Ma, S., He, Z., Fu, H., Wang, L., Wu, X., Zhang, Z., & Wang, Q. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.07 · Cited by 30
Zhou, S., Kishi, N., Alerasool, P., & Rohs, N. C. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01073-w · Cited by 30
Lu, S., Wang, J., Yang, N., Lv, D., Chen, L., Wu, L., Li, X., Sun, L., Yu, Y., Jin, B., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)01811-2 · Cited by 30
Self-citationHead and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers
Swiecicki, P. L., Brennan, J. R., Mierzwa, M. L., Spector, M. E., & Brenner, J. C. (2018) · The Laryngoscope · doi:10.1002/lary.27725 · Cited by 30
Raphael, J., Vincent, M. D., Boldt, G., Shah, P. S., Rodrigues, G., & Blanchette, P. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000533 · Cited by 30
Schüler, M., Paz-Ares, L. G., Sequist, L. V. D., Hirsh, V., Lee, K. H., Wu, Y.-L. L. C., Lü, S., Zhou, C., Feng, J., Ellis, S. H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.006 · Cited by 31
Self-citationRe, M. D., Petrini, I., Mazzoni, F., Valleggi, S., Gianfilippo, G., Pozzessere, D., Chella, A., Crucitta, S., Rofi, E., Restante, G., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.10.003 · Cited by 30
Self-citationClinical importance of long non‑coding RNA LINC00460 expression in EGFR‑mutant lung adenocarcinoma
Nakano, Y., Isobe, K., Kobayashi, H., Kaburaki, K., Isshiki, T., Sakamoto, S., Takai, Y., Tochigi, N., Mikami, T., Iyoda, A., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4919 · Cited by 30
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
Liu, X., Guo, Z., Chen, Z., Zhang, Y., Zhou, J., Jiang, Y., Zhao, Q., Diao, X., & Zhong, D. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0389-3 · Cited by 30
Ohe, Y., Kato, T., Sakai, F., Kusumoto, M., Endo, M., Saito, Y., Baba, T., Sata, M., Yamaguchi, O., Sakamoto, K., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa067 · Cited by 30
Shimizu, T., Nishio, K., Sakai, K., Okamoto, I., Okamoto, K., Takeda, M., Morishita, M., & Nakagawa, K. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04112-1 · Cited by 30
Zhao, B., Wang, Y., Wang, Y., Chen, W., Zhou, L., Liu, P. H., Kong, Z., Dai, C., Wang, Y., & Ma, W. (2020) · Aging · doi:10.18632/aging.103455 · Cited by 30
Madison, R. W., Schrock, A. B., Castellanos, E. H., Gregg, J. P., Snider, J. W., Ali, S. M., Miller, V. A., Singal, G., Alexander, B. M., Venstrom, J. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.033 · Cited by 30
Soares, M., Antunes, L., Redondo, P., Borges, M., Hermans, R., Patel, D., Grimson, F., Munro, R. E. J., Chaib, C., Lacoin, L., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01270-z · Cited by 30
Province-Wide Analysis of Patient-Reported Outcomes for Stage IV Non-Small Cell Lung Cancer
Tjong, M. C., Doherty, M. K., Tan, H., Chan, W. C., Zhao, H., Hallet, J. I., Darling, G. E., Kidane, B., Wright, F. C., Mahar, A. L., et al. (2021) · The Oncologist · doi:10.1002/onco.13890 · Cited by 31
Zhang, Z., Xu, P., Hu, Z., Fu, Z., Deng, T., Deng, X., Peng, L., Xie, Y., Long, L., Zheng, D., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69332 · Cited by 30
Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 31
Leszek, P., Klotzka, A., Bartuś, S., Burchardt, P., Czarnecka, A. M., Długosz‐Danecka, M., Gierlotka, M. J., Koseła-Paterczyk, H., Krawczyk‐Ożóg, A., Kubiatowski, T., et al. (2023) · Kardiologia Polska · doi:10.33963/v.kp.96840 · Cited by 31
Baglivo, S., Ludovini, V., Sidoni, A., Metro, G., Ricciuti, B., Siggillino, A., Rebonato, A., Messina, S. G., Crinò, L., & Chiari, R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.03.022 · Cited by 30
Watanabe, S., Yoshida, T., Kawakami, H., Takegawa, N., Tanizaki, J., Hayashi, H., Takeda, M., Yonesaka, K., Tsurutani, J., & Nakagawa, K. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0351 · Cited by 30
Cardiac Dysfunction Caused by Osimertinib
Oyakawa, T., Nakashima, K., & Naito, T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.016 · Cited by 30
Klempner, S. J., Mehta, P., Schrock, A. B., Ali, S. M., & Ou, S. I. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s147129 · Cited by 30
Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration
Hwang, W. L., Pleskow, H. M., & Miyamoto, D. T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.003 · Cited by 30
Li, W., Qiu, T., Ling, Y., Gao, S., & Ying, J. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12190 · Cited by 30
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 32
Strategies to Preserve Cognition in Patients With Brain Metastases: A Review
Robin, T. P., & Rusthoven, C. G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00415 · Cited by 31
Safety of osimertinib in EGFR -mutated non-small cell lung cancer
Mezquita, L., Varga, A., & Planchard, D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1549222 · Cited by 31
Saturation profiling of drug-resistant genetic variants using prime editing
Kim, Y., Oh, H.-C., Lee, S., & Kim, S. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02465-z · Cited by 30
Cancer brain metastasis: molecular mechanisms and therapeutic strategies
Lu, Y., Huang, Y., Zhu, C., Li, Z., Zhang, B., Sheng, H., Li, H., Liu, X., Xu, Z., Wen, Y., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00251-0 · Cited by 29
Fernández‐Ruiz, M., García‐Campelo, R., Garrido-Castro, A. C., & Ruíz-Camps, I. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.027 · Cited by 29
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
Zaman, A., & Bivona, T. G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.02 · Cited by 29
Uchibori, K., Inase, N., Nishio, M., Fujita, N., & Katayama, R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.005 · Cited by 32
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Takahashi, Y., Kuroda, H., Oya, Y., Matsutani, N., Matsushita, H., & Kawamura, M. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13133 · Cited by 29
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
Ninomiya, K., Teraoka, S., Zenke, Y., Kenmotsu, H., Nakamura, Y., Okuma, Y., Tamiya, A., Nosaki, K., Morise, M., Aokage, K., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100107 · Cited by 29
Zengin, Z. B., Weipert, C. M., Salgia, N., Dizman, N., Hsu, J., Meza, L., Chehrazi‐Raffle, A., Muddasani, R., Salgia, S. K., Malhotra, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0572 · Cited by 29
Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
Suda, K., & Mitsudomi, T. (2021) · Cells · doi:10.3390/cells10071590 · Cited by 30
Popat, S., Jung, H. A., Lee, S. Y., Hochmair, M. J., Lee, S. H., Escriu, C., Lee, M. K., Migliorino, M. R., Lee, Y. C., Girard, N., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.009 · Cited by 29
Biomedical Applications of Non-Small Cell Lung Cancer Spheroids
Rozenberg, J. M., Filkov, G. I., Trofimenko, A. V., Karpulevich, E., Parshin, V. D., Royuk, V. V., Sekacheva, M. I., & Durymanov, M. O. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.791069 · Cited by 30
Kolesar, J., Peh, K. H., Thomas, L., Baburaj, G., Mukherjee, N., Kantamneni, R., Lewis, S. C., Pai, A., Udupa, K., Kumar, N. A. N., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01534-8 · Cited by 32
Nieva, J. J., Reckamp, K. L., Potter, D. M., Taylor, A., & Sun, P. (2022) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00302-w · Cited by 29
Li, Y., Kong, S., Liu, Y., Yang, Y., & Zhang, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041438 · Cited by 29
Yang, F., Gong, J., Li, M., Jiang, X., Zhang, J., Liao, M., Zhang, H., Tremblay, P., & Zhang, T. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02649 · Cited by 29
Li, Y., Xu, H., Su, S., Ye, J., Chen, J., Jin, X., Lin, Q. D., Zhang, D., Ye, C., & Chen, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183331 · Cited by 30
EGFR-TKIs in Non-Small-Cell Lung Cancer: Focus on Clinical Pharmacology and Mechanisms of Resistance
Fogli, S., Polini, B., Re, M. D., Petrini, I., Passaro, A., Crucitta, S., Rofi, E., & Danesi, R. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0038 · Cited by 29
Song, Z., Wang, H., Yu, Z., Lu, P., Xu, C., Chen, G., & Zhang, Y. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.007 · Cited by 30
Marrocco, I., & Yarden, Y. (2023) · Cancers · doi:10.3390/cancers15205009 · Cited by 28
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 28
Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
Mazza, V., & Cappuzzo, F. (2017) · The Application of Clinical Genetics · doi:10.2147/tacg.s103471 · Cited by 28
Acquired Resistance in Oncogene-Addicted Non-Small-Cell Lung Cancer
Sini, C., Tuzi, A., Rossi, G., Russo, A., & Pezzuto, A. (2018) · Future Oncology · doi:10.2217/fon-2018-0097 · Cited by 29
Oh, D. K., Ji, W., Kim, W. S., Choi, C., Yoon, S., Rho, J. K., & Lee, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210225 · Cited by 28
Girard, N. (2019) · Future Oncology · doi:10.2217/fon-2019-0400 · Cited by 29
Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., et al. (2019) · Cancer · doi:10.1002/cncr.32481 · Cited by 28
Buder, A., Hochmair, M. J., Setinek, U., Pirker, R., & Filipits, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.02 · Cited by 28
Yamaguchi, O., Kaira, K., Shinomiya, S., Mouri, A., Hashimoto, K., Shiono, A., Miura, Y., Akagami, T., Imai, H., Kobayashi, K., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13725 · Cited by 28
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development
Pal, A., Shinde, R., Miralles, M. S., Workman, P., & Bono, J. S. D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00489-x · Cited by 28
Gray, J. E., Thompson, J. C., Carpenter, E. L., Elkhouly, E., & Aggarwal, C. (2021) · The Oncologist · doi:10.1002/onco.13889 · Cited by 28
Tsubata, Y., Tanino, R., & Isobe, T. (2021) · Cells · doi:10.3390/cells10113192 · Cited by 31
Majem, M., Goldman, J. W., John, T., Grohe, C., Laktionov, K., Kim, S.-W., Kato, T., Vũ, H. V., Lu, S., Li, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3530 · Cited by 28
Self-citationComplications following novel therapies for non‐small cell lung cancer
Skribek, M., Rounis, K., Tsakonas, G., & Ekman, S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13445 · Cited by 28
Yi, Y., Li, P., Huang, Y., Chen, D., Fan, S., Wang, J., Yang, M., Zeng, S., Deng, J., Lv, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02438-z · Cited by 28
Huang, W., Li, F., Gong, Y., Zhang, Y., Youngsaye, W., Xu, Y., Zhu, X., Greenfield, M. T., Kohlmann, A., Taslimi, P. M., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129084 · Cited by 29
Lemmon, C. A., Zhou, J. H. S., Hobbs, B. P., & Pennell, N. A. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00294 · Cited by 28
Soo, R. A., de Marinis, F., Han, J., Ho, J., Martin, E. C., Servidio, L., Sandelin, M., & Popat, S. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.09.005 · Cited by 28
Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study
Zhao, H., Cao, J., Chang, J., Zhang, Z., Yang, L., Wang, J., Cantarini, M., & Zhang, L. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1042 · Cited by 28
Metformin‐sensitized NSCLC cells to osimertinib via AMPK‐dependent autophagy inhibition
Chen, H., Lin, C., Lu, C., Wang, Y., Han, R., Li, L., Hao, S., & He, Y. (2019) · The Clinical Respiratory Journal · doi:10.1111/crj.13091 · Cited by 28
Self-citationCancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation
Oikawa, M., Ishida, T., & Takeishi, Y. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.04.006 · Cited by 27
Cutting-Edge AI Technologies Meet Precision Medicine to Improve Cancer Care
Lin, P., Tsai, Y.-S., Yeh, Y., & Shen, M.-R. (2022) · Biomolecules · doi:10.3390/biom12081133 · Cited by 27
Grazini, U., Markovets, A. A., Ireland, L., O’Neill, D. J., Phillips, B., Xu, M., Pfeifer, M., Vaclová, T., Martin, M. J., Bigot, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2540 · Cited by 27
Hong, M. H., Choi, Y. J., Ahn, H. K., Lim, S. M., Keam, B., Kim, D., Kim, T. M., Youk, J., Kim, Y. J., Hwang, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2640 · Cited by 27
Self-citationGawli, C., Patil, C. R., & Patel, H. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118146 · Cited by 27
Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer
Hage, M. E., Su, Z., & Linnebacher, M. (2025) · Cancers · doi:10.3390/cancers17071098 · Cited by 27
Venetsanakos, E., Brameld, K. A., Phan, V. T., Verner, E. J., Owens, T. D., Xing, Y., Tam, D., LaStant, J., Leung, K., Karr, D. E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0309 · Cited by 27
Saito, R., Miki, Y., Ishida, N., Inoue, C., Kobayashi, M., Hata, S., Yamada‐Okabe, H., Okada, Y., & Sasano, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020609 · Cited by 27
First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
Bulbul, A., & Husain, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00094 · Cited by 28
Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
Heydt, C., Michels, S. Y. F., Thress, K. S., Bergner, S., Wolf, J., & Buettner, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24624 · Cited by 27
Li, X., Wang, S., Li, B., Wang, Z., Shang, S., Shao, Y. W., Sun, X., & Wang, L. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0573-2 · Cited by 28
Hirashima, T., Satouchi, M., Hida, T., Nishio, M., Kato, T., Sakai, H., Imamura, F., Kiura, K., Okamoto, I., Kasahara, K., et al. (2019) · Cancer Science · doi:10.1111/cas.14120 · Cited by 27
Cortellini, A., Leonetti, A., Catino, A., Pizzutilo, P., Ricciuti, B., Giglio, A. D., Chiari, R., Bordi, P., Santini, D., Giusti, R., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02193-w · Cited by 28
Jia, Y., Zhao, S., Jiang, T., Li, X., Zhao, C., Liu, Y., Han, R., Qiao, M., Liu, S., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.016 · Cited by 27
Bergonzini, C., Leonetti, A., Tiseo, M., Giovannetti, E., & Peters, G. J. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1746269 · Cited by 28
Metadata
- Authors
- Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., Lee, C. K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., & Papadimitrakopoulou, V. A.
- Affiliations
- Army Medical University (CN)
- Emory University (US)
- Goethe University Frankfurt (DE)
- AstraZeneca (United Kingdom) (GB)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-02-16
- Volume
- 376
- Issue
- 7
- Pages
- 629-640
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6762027
- OpenAlex
- W2560717039
- Semantic Scholar
- bd8840946a65bec6d407a96092eda55497e49a58
- Cited by
- 3,379
- References
- 25
- Citations by year
- 2026: 198 · 2025: 280 · 2024: 301 · 2023: 318 · 2022: 410 · 2021: 438 · 2020: 404 · 2019: 365 · 2018: 389 · 2017: 268
- FWCI
- 305.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Funders
- Cancer Research UK (20465)
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- osimertinib, T790M mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, pemetrexed, carboplatin, cisplatin, second-line therapy, progression-free survival, central nervous system metastasis, brain metastases, objective response rate, adverse events
- MeSH terms
- Pemetrexed, Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Platinum, Pyrimidines, Disease-Free Survival, Young Adult, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
